📅 PUBMED DAILY TRIAGE — 2026-05-19

Window: 2026-05-18T09:03Z → 2026-05-19T09:00Z (CRDT)
Topics scanned: 9 watchlist + sentinel | Articles reviewed: ~80 candidates | Abstracts evaluated: 30
High priority: 3 | Standard: 16 | Low/archive: 4 | Unsolicited finds: 1
Run status: ✅ SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

AI/ML in Clinical Diagnostics + Early Cancer Detection

TR-2026-05-19-001 · PMID 42151338 · NPJ Digital Medicine · 9/10 🔴 EARLY_CANCER_DETECTION
Prospective deployment of AI-based risk stratification to enable expedited mammography workflow in a safety-net setting
→ Mirai AI flagged top 10% risk from 4145 mammograms at UCSF safety-net; 100 expedited patients had 99.1% faster time to diagnosis and a cancer detection rate of 60/1000 vs 2.3/1000 in non-high-risk. Real-world disparity reduction, prospectively validated.

Cardiovascular-Metabolic / GLP-1

TR-2026-05-19-002 · PMID 42151525 · J Gen Intern Med · 8/10 🟠 NOVEL_TREATMENT
GLP-1 Receptor Agonist Treatment and Health Outcomes in Methadone-Treated Patients with Opioid Use Disorder and Diabetes
→ In 2314 PSM-matched OUD+T2D patients on methadone, GLP-1 RA use was associated with 42% lower MI (HR 0.58), 75% higher OUD remission (HR 1.75), and 73% lower suicidal thoughts (HR 0.27) — a striking multi-domain benefit signal in a high-risk underserved population.

Novel Therapeutics

TR-2026-05-19-003 · PMID 42151633 · Nature Cardiovascular Research · 8/10 🟠 NOVEL_TREATMENT
Single-cell and spatial transcriptomics identify immune-stromal interactions in cardiac allograft vasculopathy
→ scRNA-seq + spatial transcriptomics of human CAV coronary arteries identified type 1 IFN signaling as the dominant driver; ruxolitinib reduced CAV incidence and prolonged allograft survival in mice. First mechanistic therapeutic target for a condition with no disease-modifying therapies.

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)

• TR-2026-05-19-004 · PMID 42151619 · ML+PET/CT radiomics for GI lymphoma perforation prediction (multicenter, n=257, AUC 0.852 external) · 7/10 · Diagnostics
• TR-2026-05-19-009 · PMID 42151711 · Darbepoetin alfa MDS post-marketing surveillance Japan (n=1834, 5-year data; 40.9% transfusion independence at yr4-5) · 6/10 · Treatment Innovation
• TR-2026-05-19-014 · PMID 42151585 · Zanubrutinib + polatuzumab vedotin synergism in DLBCL via CD79b upregulation (preclinical in vitro/in vivo) · 5/10 · Drug Development
• CBC/ML hematology: No high-priority finds today (best candidate scored 3/10 — no true CBC+ML match in window; 4th+ consecutive run without HIGH article)

Early Cancer Detection (Liquid Biopsy, ctDNA, cfDNA)

• TR-2026-05-19-016 · PMID 42151663 · Exhaled breath condensate metabolomics for thyroid+breast cancer (GC-MS, n=74, AUC 0.822 TC / 0.783 BC) · 5/10 · Promising preliminary — very small n
• TR-2026-05-19-019 · PMID 42151560 · CTC-derived xenograft preclinical platform for metastatic breast cancer (single patient, Br J Cancer) · 4/10 · LOW

AI/ML in Clinical Diagnostics and Imaging

• TR-2026-05-19-005 · PMID 42151660 · Landmark-guided dual-stream DL for intracranial aneurysm detection on MRA (n=1055, sensitivity 0.87, FP 1.23/case) · 7/10 · Diagnostics
• TR-2026-05-19-010 · PMID 42151627 · Explainable ML for surgical prediction in pediatric intestinal obstruction (AUC 0.981 external, SHAP, n=779) · 6/10 · Diagnostics
• TR-2026-05-19-011 · PMID 42151593 · ML for sepsis-AKI in pediatric patients (Phoenix criteria, n=2424) · 6/10 · Diagnostics

Precision Oncology and Genomic Medicine

• TR-2026-05-19-008 · PMID 42151367 · Lorlatinib in ALK-driven neuroblastoma (n=25, ORR 64.7%; 100% ORR in ALK hotspot-only; NPJ Precision Oncology) · 7/10 · Treatment Innovation
• TR-2026-05-19-015 · PMID 42151323 · Post-Chornobyl thyroid PTC multi-omic exposure vs carcinogenesis signatures (miRNome + RNA-seq) · 5/10 · Genomics
• TR-2026-05-19-022 · PMID 42151650 · Basal cell subsets as neoadjuvant response biomarkers in ESCA (scRNA-seq, n=22) · 5/10 · Genomics

Cardiovascular-Metabolic / GLP-1 / SGLT2

• TR-2026-05-19-006 · PMID 42151744 · SPRINT/PWV substudy: intensive BP control reduces LD-PWV → 21% lower cognitive impairment risk (n=614, 10-year follow-up) · 7/10 · Prevention
• TR-2026-05-19-012 · PMID 42151563 · ED + low testosterone as early cardiometabolic markers (n=3.5M TriNetX, HR 2.54 for CVD in ED group) · 6/10 · Diagnostics

Aging, Longevity, and Population Health

• SPRINT/PWV substudy (42151744) shared here — see Cardiometabolic section above
• TR-2026-05-19-007 · PMID 42151737 · LIBRA index + cognitive function, German National Cohort n=149,948; modifiable risks associated with worse cognition from age 20+ · 7/10 · Prevention

Rare Diseases with High Unmet Need

• TR-2026-05-19-017 · PMID 42151490 · Acromelic dysplasias 12 Turkish patients, 5 novel variants in ADAMTSL2/ADAMTS10/ADAMTS17, 8-year longitudinal follow-up · 5/10 · Genomics
• No HIGH-priority finds today (best candidate scored 5/10)

💡 UNSOLICITED FINDS

TR-2026-05-19-013 · PMID 42151741 · Head & Neck · 6/10
Age Does Not Influence Cancer Mortality After Transoral Laser Microsurgery for Glottic Cancer (n=676, competing-risks analysis)
→ In 676 patients with laryngeal SCC (2000-2025), age strongly predicted overall survival (HR 1.90/decade) but was NOT significant for cancer-specific mortality in competing-risk analysis. Tumor stage and margin status dominated. Supports tumor biology—not age—as primary treatment eligibility criterion.

📊 TODAY'S BREAKDOWN

By research category:

• Early Detection: 2 | Treatment Innovation: 6 | Diagnostics: 7 | Genomics/Precision Medicine: 5 | Prevention: 2 | Drug Development: 2 | Public Health: 1

By evidence maturity:

• Exploratory: 13 | Validated: 10 | Potentially Practice-Changing: 0

By watchlist topic (reviewed / kept / highest score):

By source type: peer_reviewed: 23 | preprint: 0

Topics with zero 8+ articles this run:

• Hematologic malignancies (best: 7)
• CBC/ML hematology (best: 3 — zero qualifying candidates)
• Precision oncology/genomics (best: 7)
• Aging/longevity (best: 7)
• Rare diseases (best: 5)

🔧 RUN NOTES

• Window expansion: NOT triggered (23 articles across topics; well above 5-article minimum).
• CBC/ML hematology persistent gap: 0 HIGH articles for 4th+ consecutive run. Today's CRDT window returned only 1 result (PMID 42151335 — serum progranulin for neonatal sepsis, not a direct CBC+ML hematology article). Recommend query reformulation: broaden to (hematology OR hematopoietic) AND (machine learning OR artificial intelligence OR automated differential) in future runs.
• humans[MeSH] filter on aging topic: Maintained per v1.2 note. Returned 66 results today; no non-human contamination observed in top 10.
• Errata excluded (5 items): PMID 42151574 (tirzepatide/CPAP survey correction), 42151417 (Nat Genet RNU4-2 author correction), 42151694 (Nature GLP-1R quintuple agonism publisher correction), 42151718 (febuxostat review correction), 42151740 (ACS Appl Mater Interfaces — materials science, out of scope). These were deducted before counting.
• Rolling 7-day view — consistently sparse topics: CBC/ML hematology has produced 0 HIGH articles for ≥4 consecutive runs. Rare diseases has not produced a HIGH article in the last 4 runs reviewed.
• Alert cap: 3 HIGH articles found — all 3 sent as alerts (within 5-alert cap).
• Key signal of the day: AI mammography at safety-net (PMID 42151338, 9/10) — strongest finding, prospective real-world deployment with dramatic disparity reduction. GLP-1 RA in OUD+T2D (PMID 42151525, 8/10) — unexpected and striking multi-benefit signal across addiction/cardiometabolic/psychiatric domains.